S1R fundamentals
An in-depth look to SHANGHAI PHARM.HLDG H YC1 operating, investing, and financing activities
S1R free cash flow for Q1 24 is -801.76 M EUR. For 2023, S1R free cash flow was 415.76 M EUR and operating cash flow was 796.52 M EUR.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM